A Phase 2 interventional study of AG10 and Placebo Oral Tablet in Familial ATTR-CM (ATTRm-CM, or FAC) and Wild-type ATTR-CM (ATTRwt-CM), sponsored by Eidos Therapeutics, a BridgeBio company. Completed at 13 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-16.
Sponsored by Eidos Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK (Pharmacokinetic) and PD (Pharmacodynamic) of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period.
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy.
The primary objective of this study is to evaluate the safety and tolerability of AG10 administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTRCM).
This study will be a Phase 2, randomized, placebo-controlled, dose-ranging study in 45 male and/or female patients with symptomatic ATTR-CM aged 18 through 90 years.
If all doses are well tolerated, the duration of each patient's participation in the study will be 28 days of treatment. In addition, there will be a 28-day screening period before treatment and a 30-day follow-up period before the final Follow-up Visit.
This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK and PD of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period. secondary objectives of this study are: to characterize the pharmacokinetics (PK) of AG10 administered orally twice daily in patients with symptomatic ATTRCM, and to describe the pharmacodynamic (PD) properties of AG10 as assessed by established assays of transthyretin (TTR) stabilization, including Fluorescent Probe Exclusion (FPE) assay and Western blot, and to describe the Pharmacokinetic Pharmacodynamic (PKPD) relationship of AG10 in adult patients with symptomatic ATTRCM.
Eligible patients will be randomized in a 1:1:1 ratio to placebo or one of two different doses of AG10 administered twice daily. A minimum of 30% of patients enrolled will be mutant ATTR-CM.
Eidos Therapeutics, a BridgeBio company is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
First submitted after Eidos Therapeutics became part of BridgeBio.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AG10 400mg tablets twice daily for 28 days
Drug: AG10
AG10 800mg tablets twice daily for 28 days
Drug: AG10
Placebo tablets twice daily for 28 days
Drug: Placebo Oral Tablet
TTR stabilizer
Nonactive control
Change in Diastolic Blood Pressure
Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose)
Time frame: Baseline to Day 28
Change in Heart Rate
Change in Heart Rate from Baseline to Day 28 (Postdose)
Time frame: Baseline to Day 28
Change in Respiratory Rate
Change in Respiratory Rate from Baseline to Day 28 (Postdose)
Time frame: Baseline to Day 28
Change in Temperature
Change in Temperature from Baseline to Day 28
Time frame: Baseline to Day 28
Change in Systolic Blood Pressure
Change in Systolic Blood Pressure from Baseline to Day 28
Time frame: Baseline to Day 28
Number of Participants With Threshold Levels of Overall % Stabilization >= 95% and >= 99% by Fluorescent Probe Exclusion (FPE)
In specialized lab tests on patient samples that measure the stability of the healthy form of TTR, both doses of AG10 were able to reach near complete stabilization.
Time frame: Day 1 to Day 28
Pharmacokinetic (PK): Steady State Trough Concentration of AG10
Non-fluctuating minimal amount of AG10 in blood at Day 14 and Day 28
Time frame: Day 14 and Day 28
| Milestone | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| Started | 16 | 16 | 17 |
| Screening | 16 | 16 | 17 |
| Double blind treatment | 16 | 16 | 17 |
| Follow-up | 16 | 16 | 17 |
| Completed | 16 | 16 | 17 |
| Not completed | 0 | 0 | 0 |
Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose)
| mm Hg | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| Change in Diastolic Blood Pressure from Baseline to Day 28 (Predose) | -3.1 ± 10.06 | -3.3 ± 11.19 | -4.3 ± 7.78 |
| Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose) | -2.6 ± 9.66 | 0.3 ± 8.54 | -4.9 ± 9.17 |
Change in Heart Rate from Baseline to Day 28 (Postdose)
| beats/minute | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| Change in heart rate from Baseline to Day 28 (Predose) | -2.7 ± 6.88 | -3.8 ± 6.55 | -0.4 ± 6.34 |
| Change in heart rate from Baseline to Day 28 (Postdose) | -7.3 ± 9.84 | -4.9 ± 5.84 | -1.1 ± 8.89 |
Change in Respiratory Rate from Baseline to Day 28 (Postdose)
| breaths/minute | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| Change in Respiratory Rate from Baseline to Day 28 (Predose) | -0.1 ± 2.23 | -0.8 ± 3.12 | -0.4 ± 2.35 |
| Change in Respiratory Rate from Baseline to Day 28 (Postdose) | -0.7 ± 1.68 | -1.1 ± 3.11 | -1.1 ± 2.93 |
Change in Temperature from Baseline to Day 28
| degrees Celsius | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| Change in Temperature from Baseline to Day 28 (Predose) | 0.17 ± 0.793 | 0.06 ± 0.316 | -0.08 ± 0.506 |
| Change in Temperature from Baseline to Day 28 (Postdose) | 0.22 ± 0.781 | -0.02 ± 0.357 | 0.02 ± 0.194 |
Change in Systolic Blood Pressure from Baseline to Day 28
| mm Hg | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| Change in Systolic Blood Pressure from Baseline to Day 28 (Predose) | -2.7 ± 12.05 | -8.1 ± 12.36 | -5.3 ± 13.50 |
| Change in Systolic Blood Pressure from Baseline to Day 28 (Postdose) | -2.8 ± 18.41 | -4.1 ± 8.88 | -3.4 ± 17.51 |
In specialized lab tests on patient samples that measure the stability of the healthy form of TTR, both doses of AG10 were able to reach near complete stabilization.
| Participants | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| % Stabilization > = 95 % | 14 | 15 | 0 |
| % Stabilization > = 99 % | 11 | 13 | 0 |
Non-fluctuating minimal amount of AG10 in blood at Day 14 and Day 28
| ng/mL | AG10 400mg | AG10 800mg |
|---|---|---|
| AG10: PK Plasma Concentration at Day 14 (Pre-Dose) | 1924.4 ± 837.3 | 2257.3 ± 982.81 |
| AG10: PK Plasma Concentration at Day 28 (Pre-Dose) | 1841.3 ± 483.88 | 2439.4 ± 900.08 |
Collected over Onset date on or after first dose of study drug and not more than 30 days after last dose of study drug, up to day 58.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG10 400mg | 0/16 (0%) | 1/16 (6.3%) | 10/16 (62.5%) |
| AG10 800mg | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| Placebo | 0/17 (0%) | 2/17 (11.8%) | 15/17 (88.2%) |
| Event | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/16 | 0/16 | 0/17 |
| Atrial FibrillationCardiac disorders | 0/16 | 0/16 | 1/17 |
| Cardiac Failure CongestiveCardiac disorders | 0/16 | 0/16 | 1/17 |
| CellulitisInfections and infestations | 0/16 | 0/16 | 1/17 |
| Event | AG10 400mg | AG10 800mg | Placebo |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/16 | 3/16 | 2/17 |
| DiarrhoeaGastrointestinal disorders | 2/16 | 3/16 | 0/17 |
| PalpitationsCardiac disorders | 0/16 | 0/16 | 3/17 |
| Atrial FibrillationCardiac disorders | 1/16 | 2/16 | 0/17 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 0/16 | 2/16 | 1/17 |
| DizzinessNervous system disorders | 0/16 | 2/16 | 0/17 |
| Oedema PeripheralGeneral disorders | 2/16 | 0/16 | 0/17 |
| Venous Pressure Jugular IncreasedInvestigations | 2/16 | 0/16 | 0/17 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 1/16 | 1/16 | 2/17 |
| HeadacheNervous system disorders | 0/16 | 1/16 | 2/17 |
| Age, Continuous(Years) | AG10 400mg | AG10 800mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 73.8 ± 5.65 | 75.4 ± 6.81 | 73.2 ± 7.35 | 74.1 ± 6.58 |
| Sex: Female, Male(Participants) | AG10 400mg | AG10 800mg | Placebo | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 0 | 4 |
| Male | 14 | 14 | 17 | 45 |
| Ethnicity (NIH/OMB)(Participants) | AG10 400mg | AG10 800mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 | 4 |
| Not Hispanic or Latino | 14 | 14 | 15 | 43 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | AG10 400mg | AG10 800mg | Placebo | Total |
|---|---|---|---|---|
| Race (NIH/OMB) — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race (NIH/OMB) — Asian | 1 | 0 | 0 | 1 |
| Race (NIH/OMB) — Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 |
| Race (NIH/OMB) — Black or African American | 4 | 3 | 3 | 10 |
| Race (NIH/OMB) — White | 10 | 12 | 13 | 35 |
| Race (NIH/OMB) — Other | 1 | 1 | 1 | 3 |
| Race (NIH/OMB) — More than one race | 0 | 0 | 0 | 0 |
| Race (NIH/OMB) — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | AG10 400mg | AG10 800mg | Placebo | Total |
|---|---|---|---|---|
| United States | 16 | 16 | 17 | 49 |
| Body Mass Index (BMI)(kg/meters squared) | AG10 400mg | AG10 800mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 25.42 ± 3.284 | 26.29 ± 3.705 | 27.05 ± 3.604 | 26.27 ± 3.528 |
| Height(Centimeters) | AG10 400mg | AG10 800mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 172.68 ± 7.055 | 175.59 ± 9.738 | 174.52 ± 8.220 | 174.27 ± 8.317 |
| TTR Genotype Status(Participants) | AG10 400mg | AG10 800mg | Placebo | Total |
|---|---|---|---|---|
| Wild Type | 10 | 11 | 14 | 35 |
| Mutant | 6 | 5 | 3 | 14 |
| Other | 0 | 0 | 0 | 0 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Oct 2018, 5 months.
Results were first posted in Nov 2022, 4 years 1 month after primary completion. A results delay was requested in Nov 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acoramidis
Eidos Therapeutics, a BridgeBio company →